摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one | 1620675-86-6

中文名称
——
中文别名
——
英文名称
(6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one
英文别名
(6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyl-1,5,6,7,8,8a-hexahydro-[1,3]oxazolo[3,4-a]pyridin-3-one
(6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one化学式
CAS
1620675-86-6
化学式
C14H16BrN5O2
mdl
——
分子量
366.217
InChiKey
HMGXLYVWHFWZDW-ASODMVGOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    85.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • BTK INHIBITORS
    申请人:KIM RONALD M.
    公开号:US20140206681A1
    公开(公告)日:2014-07-24
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    本发明提供了根据式I提供的Bruton's酪氨酸激酶(Btk)抑制剂化合物,或其药学上可接受的盐,或包含这些化合物的药物组合物,并且用于治疗的使用。具体地,本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。
  • US9481682B2
    申请人:——
    公开号:US9481682B2
    公开(公告)日:2016-11-01
  • [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK
    申请人:MERCK SHARP & DOHME
    公开号:WO2016109221A1
    公开(公告)日:2016-07-07
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    本发明提供布鲁顿酪氨酸激酶(Btk)抑制剂化合物,根据公式I,或其药用可接受的盐,公式I,或包含这些化合物的药物组合物,以及它们在治疗中的用途。特别是,本发明涉及在治疗Btk介导的疾病中使用公式I的Btk抑制剂化合物。
  • Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
    作者:Jian Liu、Deodial Guiadeen、Arto Krikorian、Xiaolei Gao、James Wang、Sobhana Babu Boga、Abdul-Basit Alhassan、Wensheng Yu、Oleg Selyutin、Younong Yu、Rajan Anand、Jiayi Xu、Joseph Kelly、Joseph L. Duffy、Shilan Liu、Chundao Yang、Hao Wu、Jiaqiang Cai、Chad Bennett、Kevin M. Maloney、Sriram Tyagarajan、Ying-Duo Gao、Thierry O. Fischmann、Jeremy Presland、My Mansueto、Zangwei Xu、Erica Leccese、Jie Zhang-Hoover、Ian Knemeyer、Charles G. Garlisi、Peter Stivers、Philip E. Brandish、Alexandra Hicks、Ronald Kim、Joseph A. Kozlowski
    DOI:10.1016/j.bmcl.2020.127390
    日期:2020.9
    Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition, and for the treatment of B cell related diseases. Many BTK inhibitors have been discovered for the treatment of cancer and rheumatoid arthritis, including a series of BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine we recently reported. The X-ray crystal structures of BTK with inhibitors were also published, which provided great help for the SAR design. Here we report our SAR work introducing ring constraints for the 3-position piperidine amides on the BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine. This modification improved the potency in BTK inhibitions, as well as the PK profile and the off-target selectivity. The dose-dependent efficacy of two BTK inhibitors was observed in the rat collagen induced arthritis (CIA) model.
查看更多

同类化合物

顺式-3-(8-氨基-1-溴咪唑并[1,5-a]吡嗪-3-基)-1-甲基环丁醇 咪唑并[1,5-a]吡嗪-8-胺 咪唑并[1,5-a]吡嗪-8(7H)-硫酮 N-(2,6-二甲基苯基)-5-(4-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 N-(2,6-二甲基苯基)-5-(3-甲氧基苯基)咪唑并[1,5-a]吡嗪-8-胺 8-氯咪唑并[1,5-a]吡嗪 8-氯咪唑并[1,5-A]吡嗪-1-甲酸乙酯 8-氯-3-环丁基-1-碘-咪唑并[1,5-a]吡嗪 8-氯-3-异丙基咪唑并[1,5-A]吡嗪 5H,10H-二咪唑并[1,5-a:1, 5-d] 吡嗪-5,10-二酮 5-溴-7-(4-甲氧基苄基)咪唑并[1,5-a]吡嗪-8-(7H)-酮 5-(4-甲氧基苯基)-7H-咪唑并[1,5-a]吡嗪-8-酮 5,10-二氧代-5H,10H-二咪唑并[1,5-a:1',5'-d]吡嗪-1,6-二甲酸 3-甲基咪唑并[1,5-a]吡嗪-8(7H)-硫酮 3-甲基咪唑并[1,5-A]吡嗪 3-环己基咪唑并[1,5-a]吡嗪 3-环丁基-1-碘-咪唑并[1,5-a]吡嗪-8-胺 3-(甲硫基)-1-硝基-咪唑并[1,5-a]吡嗪 3-(甲氧基甲基)-咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯咪唑并[1,5-a]吡嗪 3-(叔丁基)-8-氯-1-碘咪唑并[1,5-a]吡嗪 3-(三氟甲基)咪唑并[1,5-a]吡嗪 3-(8-BROMO-1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 3-(1-CHLOROH-PYRROLO[1,2-A]PYRAZIN-6-YL)CYCLOBUTANONE无结构图 1-碘-3-叔丁基咪唑并[1,5-a]吡嗪-8-胺 1-溴-3-甲基-咪唑并[1,5-a]吡嗪 1-溴-3-(四氢-2H-吡喃-4-基)咪唑并[1,5-a]吡嗪-8-胺 (S)-1-bromo-8-methyl-3-(pyrrolidin-3-yl)imidazo[1,5-a]pyrazine hydrochloride tert-butyl (4-(1-bromo-3-isopropylimidazo[1,5-a]pyrazin-5-yl)cyclohex-3-en-1-yl)(methyl)carbamate 8-chloro-5-phenylimidazo[1,5-a]pyrazine 3-(6-(1,4-diazepan-1-yl)pyridin-2-yl)-6-(6-methylpyrazin-2-yl)imidazo[1,5-a]pyrazine N-(2,6-dimethylphenyl)-5-{3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}imidazo[1,5-a]pyrazin-8-amine 3-bromo-8-chloroimidazo[1,5-a]pyrazine N3-(2,4-Dichloro-phenyl)-N8,N8-diethyl-1-methyl-imidazo[1,5-a]pyrazine-3,8-diamine 7-(3-fluorobenzyl)-6-methyl-3(S)-(3-methyltetrahydrofuran-3-yl)imidazo[1,5-a]pyrazin-8(7H)-one E-1-(6,7-dimethyl-8-oxo-7,8-dihydroimidazo[1,5-a]pyrazin-1-yl)-2-ethyl-3-phenylisothiourea 7-(3-chloro-4-methoxybenzyl)-6-methyl-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one 8-chloro-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazine 3-cyclobutyl-1-(phenylethynyl)imidazo[1,5-a]pyrazin-8-amine ethyl 1-bromoimidazo[1,5-a]pyrazine-3-carboxylate Imidazo[1,5-a]pyrazine-3-carboxylic acid,1-(4-morpholinyl)-,ethyl ester Imidazo[1,5-a]pyrazine-1-methanol,8-chloro- methyl 3-methylimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine-1-methanol,8-chloro-6-methyl- Ethyl 8-Hydroxyimidazo[1,5-a]pyrazine-1-carboxylate Imidazo[1,5-a]pyrazine,8-chloro-6-phenyl- (1S,6R,8aS)-6-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-methyltetrahydro-1H-oxazolo[3,4-a]pyridin-3(5H)-one (1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)methanol 3-((1H-imidazol-1-yl)methyl)-1-bromo-8-methylimidazo[1,5-a]pyrazine 8-methyl-3-(piperidin-4-yl)imidazo[1,5-a]pyrazine